NYSE:CRL Charles River Laboratories International (CRL) Stock Price, News & Analysis $340.66 -2.03 (-0.59%) As of 12:48 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Charles River Laboratories International Stock (NYSE:CRL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CRL alerts:Sign Up Key Stats Today's Range$326.29▼$342.8350-Day Range$272.68▼$376.0352-Week Range$146.20▼$379.63Volume291,751 shsAverage Volume962,318 shsMarket Capitalization$16.32 billionP/E Ratio374.36Dividend YieldN/APrice Target$308.17Consensus RatingModerate Buy Company Overview Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics. Founded in 1947 in Boston, Charles River has grown into an international organization serving customers across multiple regions. Its headquarters are in Wilmington, Massachusetts, and its operations support research and development activities around the world.AI Generated. May Contain Errors. Read More Charles River Laboratories International Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreCRL MarketRank™: 2.380266945825 of 5 starsCharles River Laboratories International scored higher than 48% of companies evaluated by MarketBeat, and ranked 577th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.4 / 5Analyst RatingModerate Buy Consensus RatingCharles River Laboratories International has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 13 buy ratings, 3 hold ratings, and 1 sell rating.Downside RiskCharles River Laboratories International has a consensus price target of $308.17, representing about 9.5% downside from its current price of $340.66.Amount of Analyst CoverageCharles River Laboratories International has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Charles River Laboratories International's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth11.88% Earnings GrowthEarnings for Charles River Laboratories International are expected to grow by 11.88% in the coming year, from $11.45 to $12.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Charles River Laboratories International is 374.36, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.45.Price to Earnings Ratio vs. SectorThe P/E ratio of Charles River Laboratories International is 374.36, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.05.Price to Earnings Growth RatioCharles River Laboratories International has a PEG Ratio of 3.13. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCharles River Laboratories International has a P/B Ratio of 5.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.32% of the float of Charles River Laboratories International has been sold short.Short Interest Ratio / Days to CoverCharles River Laboratories International has a short interest ratio ("days to cover") of 2.23, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Charles River Laboratories International has recently increased by 5.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCharles River Laboratories International does not currently pay a dividend.Dividend GrowthCharles River Laboratories International does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.75 News SentimentCharles River Laboratories International has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Charles River Laboratories International this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for CRL on MarketBeat in the last 30 days. This is a decrease of -79% compared to the previous 30 days.MarketBeat Follows6 people have added Charles River Laboratories International to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days. Company Ownership2.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Charles River Laboratories International insiders have sold 682,189.21% more of their company's stock than they have bought. Specifically, they have bought $2,974.00 in company stock and sold $20,291,281.00 in company stock.Percentage Held by Insiders1.30% of the stock of Charles River Laboratories International is held by insiders.Percentage Held by Institutions98.91% of the stock of Charles River Laboratories International is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Charles River Laboratories International's insider trading history. Receive CRL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CRL Stock News HeadlinesCharles River Strengthens Global Microbial Solutions Network Through Investments in Manufacturing, Customer Support, and Sustainability3 hours ago | marketscreener.comMTigermed to Participate in the Privatization of Frontage Holdings Corporation and Divest Its Overseas Laboratory Services BusinessNovember 10 at 3:55 AM | prnewswire.comEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.November 12 at 1:00 AM | Behind the Markets (Ad)HK-listed Frontage to be taken private in $616 million deal backed by Charles RiverNovember 9 at 10:01 AM | reuters.comCharles River Laboratories to Acquire Frontage's Bioanalysis and DMPK BusinessesNovember 9 at 6:10 AM | businesswire.comCharles River Laboratories International (NYSE:CRL) Price Target Raised to $387.00November 8, 2026 | americanbankingnews.comCharles River Laboratories International (NYSE:CRL) Director James Foster Sells 24,042 Shares of Company StockOctober 27, 2026 | insidertrades.comCharles River Laboratories International (NYSE:CRL) Stock: Insider Shannon Parisotto Sells 2,156 SharesOctober 24, 2026 | insidertrades.comSee More Headlines CRL Stock Analysis - Frequently Asked Questions How have CRL shares performed this year? Charles River Laboratories International's stock was trading at $199.62 at the beginning of 2026. Since then, CRL stock has increased by 70.7% and is now trading at $340.6610. How were Charles River Laboratories International's earnings last quarter? Charles River Laboratories International, Inc. (NYSE:CRL) issued its quarterly earnings data on Wednesday, November, 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.12. The business's quarterly revenue was down 2.2% on a year-over-year basis. Read the conference call transcript. Does Charles River Laboratories International have any subsidiaries? Charles River Laboratories International subsidiaries include these companies: Vigene Biosciences Inc., Retrogenix Limited, Cognate BioServices, HemaCare, CiToxLAB, MPI Research, KWS BioTest, and others. Who are Charles River Laboratories International's major shareholders? Top institutional shareholders of Charles River Laboratories International include State Street Corp (29.69%), Allspring Global Investments Holdings LLC (1.86%), Aberdeen Group plc (1.66%) and Russell Investments Group Ltd. (0.91%). Insiders that own company stock include Birgit Girshick, James C Foster, Victoria L Creamer, Glenn Coleman, Joseph W Laplume, William D Barbo, Richard F Wallman, Michael Gunnar Knell, George Massaro, Shannon M Parisotto and Nancy C Andrews. View institutional ownership trends. How do I buy shares of Charles River Laboratories International? Shares of CRL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Charles River Laboratories International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Charles River Laboratories International investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), PayPal (PYPL), JPMorgan Chase & Co. (JPM), Pfizer (PFE) and Adobe (ADBE). Company Calendar Last Earnings11/04/2026Today11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CRL's financial health is in the Green zone, according to TradeSmith. CRL has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:CRL CIK1100682 Webwww.criver.com Phone(781) 222-6000Fax978-988-5665Employees19,700Year Founded1947Price Target and Rating Average Price Target for Charles River Laboratories International$308.17 High Price Target$387.00 Low Price Target$219.00 Potential Upside/Downside-9.6%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage17 Analysts Profitability EPS (Trailing Twelve Months)$0.91 Trailing P/E Ratio374.78 Forward P/E Ratio26.62 P/E Growth3.13Net Income-$144.34 million Net Margins1.01% Pretax Margin-2.52% Return on Equity16.95% Return on Assets6.93% Debt Debt-to-Equity Ratio0.76 Current Ratio1.41 Quick Ratio1.12 Sales & Book Value Annual Sales$3.98 billion Price / Sales4.11 Cash Flow$21.65 per share Price / Cash Flow15.75 Book Value$67.45 per share Price / Book5.06Miscellaneous Outstanding Shares47,917,000Free Float47,294,000Market Cap$16.34 billion OptionableOptionable Beta1.36 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NYSE:CRL) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredDo NOT Buy SpaceX Until You See “Mission X”A 30-year veteran who called Tesla before it soared 1,216% is spotlighting a company operating in the shadows ...StocksToTrade | SponsoredA Bill Would Reprice America's Gold at Market ValueThe US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,00...Concord Gold Capital | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Charles River Laboratories International, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Charles River Laboratories International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
